CYP19A1 and breast carcinoma: Ribociclib and abemaciclib are combined with an aromatase inhibitor (exemestrane, anastrozole or letrozole) or tamoxifen (abemacilib) in early disease, while the standard combinations include aromatase inhibitors or fulvestrant in advanced breast cancer.